ZYMEWORKS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
ZYMEWORKS INC. (ZYME) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of 5.64 CAD/shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2026-03-02
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2025 was 5.64 CAD/shares, a 52.00% decline from fiscal 2024.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2024 was 11.75 CAD/shares, a 6.08% decline from fiscal 2023.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2023 was 12.51 CAD/shares, a 36.91% decline from fiscal 2022.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for fiscal 2022 was 19.83 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2025-12-31 | 5.64 CAD/shares 10-K · filed 2026-03-02 |
| 2024-12-31 | 11.75 CAD/shares 10-K · filed 2025-03-05 |
| 2023-12-31 | 12.51 CAD/shares 10-K · filed 2024-03-06 |
| 2022-12-31 | 19.83 CAD/shares 10-K · filed 2023-03-07 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2025-12-31 | $4.12 10-K · filed 2026-03-02 |
| 2024-12-31 | $8.16 10-K · filed 2025-03-05 |
| 2023-12-31 | $9.44 10-K · filed 2024-03-06 |
| 2022-12-31 | $14.64 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |